51 [89Zr]Zr-DFO-girentuximab and [18F]FDG PET/CT to predict WW in mccRCC patients Figure 1. Overview of the tracer-uptake of [18F]FDG and [89Zr]Zr-DFO-girentuximab in the RECIST-measurable lesion per patient. Figure 1A depicts a scatterplot of [18F]FDG-positive and negative lesions. For each patient on the x-axis, per tumor lesion [18F]FDG SUV max is shown in vertical direction. The size of the dot reflects the size of the lesion, and the color identifies the location of this lesion. Figure 1B: identical design, here with each patient on the x-axis and the y-axis depicts the tumor [89Zr]Zr-DFO-girentuximab SUV max uptake per tumor lesion. In Figure 1C, the duration of WW is depicted for each patient, highlighting the time with and without disease progression according to RECIST 1.1. Additional imaging, clinicopathological and demographic baseline characteristics for all patients and according to high and low [18F]FDG and [89Zr]Zr-DFO-girentuximab uptake groups are shown in Table 1, imaging examples in Figure 2. 3
RkJQdWJsaXNoZXIy MTk4NDMw